Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...

As of late October, the CDC recommends a second dose of the 2024-2025 COVID-19 vaccine for at-risk groups. Here's what you ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

COVID is still circulating but Canadians' intentions to get a booster dose of a COVID-19 vaccine have decreased dramatically since 2021 You can save this article by registering for free here. Or ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

I t’s vaccination season, which for most people means getting immunized for flu and COVID-19 (and RSV for infants, pregnant ...

Dr. Elaine Ma, who was celebrated for organizing drive-thru vaccination clinics that helped thousands get their shots at the ...

On November 1, Novavax, Inc. (NASDAQ:NVAX) and the U.K. Health Security Agency, representing the U.K. Secretary of State for ...

The biotech company, which makes the Spikevax RNA-based Covid-19 vaccine, reported net income of $13 million, or 3 cents a share, compared with a loss of $3.6 billion, or $9.53 a share, in the same ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory syncytial ...

On Thursday, Moderna Inc (NASDAQ:MRNA) stock is trading higher after the company reported better-than-expected third-quarter ...

A study conducted by researchers from the CUNY Graduate School of Public Health and Health Policy (CUNY SPH) and the ...